It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
The collaboration will support Canada with direct access to rapid pandemic response capabilities
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
2DG has been given emergency approval by the Drug Controller General of India for COVID-19 patients in the country
This will enable Mangalam to reduce its reliability on Chinese imports for this product and also help to maintain an uninterrupted supply chain to a great extent
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
The Department of Pharma has allocated this drug amongst the states/UTs based on expected supply that will be available from May 10 to May 31, 2021
Subscribe To Our Newsletter & Stay Updated
